News & Publications

Zelquistinel is an Orally Bioavailable Novel NMDAR Modulator that Exhibits Rapid & Sustained Antidepressant Effects

Highlights our lead program, Zelquistinel, and it’s unique mechanism of positive NMDA receptor modulation and that enhances long-term potentiation and synaptic function, resulting in rapid and sustained antidepressant activity with an improved safety profile versus NMDA antagonists.

Repeated Administration of Rapastinel Produces Prolonged Rescue of Memory Deficits in Mice Treated with NMDAR Antagonists

Highlights the differentiated mechanism and effects on cognition of our class of NMDAR modulators, compared to NMDAR antagonists. Gate’s unique NMDAR modulator mechanism reverses and rescues brain deficits caused by NMDAR antagonists such as PCP and ketamine.

Positive Modulation of NMDA Receptors by AGN-241751 exerts rapid antidepressant effects via Excitatory Neurons

Highlights our lead program, Zelquistinel, and the novel NMDAR mechanism by which our compounds act on excitatory neurons in the mPFC, but not inhibitory neurons, to drive antidepressant effects

Cell-Type Specific Modulation of NMDA Receptors Triggers Antidepressant Actions

Highlights and differentiates the mechanistic pathways by which Gate’s NMDAR positive modulators, and NMDA antagonists (ie ketamine), can both exert rapid antidepressant effects. Gate’s NMDA modulators directly enhance receptor function on principal glutamatergic neurons in the mPFC, whereas antagonists block NMDA on GABA interneurons causing a glutamate efflux (and dissociative side effects) and indirect activation of excitatory synapse.

Rapastinel Alleviates the Neurotoxic Effects Induced by NMDA Receptor Blockade

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

NMDAR Modulators as Rapid Antidepressants, Converging and Distinct Signaling Mechanisms

Highlights data showing that Gate’s NMDAR modulators protect against the neurotoxic effects of NMDAR antagonists, especially in early neurodevelopment.

Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine

Highlights Gate’s NMDAR modulators lower propensity than ketamine to induce CNS-related adverse side effects and sleep disturbances.

Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms

Highlights how Gate’s NMDAR modulators exert rapid (within hours) and long-lasting (7-10 days) of antidepressants but without has no ketamine-like side effect such as cognitive impairment and psychotomimetic symptoms.

Positive NMDAR Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant Effects

Highlights the specific binding site and unique mechanism by which Gate’s NMDAR modulators directly enhance NMDA function in the mPFC, resulting in NMDA-mediated plasticity and rapid and sustained antidepressant activity. Also highlights the differing mechanistic actions of ketamine, and how Gate’s NMDAR modulators represent a more well-tolerated downstream approach compared to ketamine, while maintaining potent, rapid, and sustained antidepressant effects.

GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine

Highlights the molecular, cellular, and behavioral actions of Gate’s class of molecules to further characterize the mechanisms underlying their antidepressant actions  and differentiates those mechanisms from NMDAR antagonists.

1 2 3